Results 31 to 40 of about 847 (163)

Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults

Frontiers in Neurology
BackgroundMigraine is a neurological condition marked by frequent headaches, which tends to be accompanied by nausea and vomiting in severe instances. Injectable therapies for migraine, such as monoclonal antibodies that target calcitonin gene-related ...
Adarsh Raja, Rabia Asim, Muhammad Hamza Shuja, Sandesh Raja, Tazheen Saleh Muhammad, Simran Bajaj, Abdul Hadi Ansari, Hamza Ali, Iffat Ambreen Magsi, Muhammad Hammad Faridi, Hamza Ali Hasnain Sheikh, Muhammad Junaid Imran, Muhammad Ahmed, Muhammad Sohaib Asghar, Muhammad Sohaib Asghar   +14 more
doaj   +3 more sources

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system [PDF]

The Journal of Headache and Pain
Background Gepants have demonstrated notable benefits in migraine therapy, yet their safety profiles are not thoroughly investigated. This study comprehensively analyzed the adverse event (AE) risk signals of the currently approved gepants using the U.S.
Qi Song, Siyuan Gao, Yaqian Tan
doaj   +2 more sources

Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study. [PDF]

Headache
Abstract Objective To assess weight loss with atogepant 60 mg once daily during long‐term treatment of chronic migraine (CM) and episodic migraine (EM) among participants previously failed by two to four classes of conventional oral preventive medications.
Bond DS, Smith JH, Sinclair A, Goadsby PJ, Ailani J, Liu Y, De Abreu Ferreira R, Dabruzzo B, Trugman JM, Peterlin BL.   +9 more
europepmc   +2 more sources

The pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies. [PDF]

Headache
Abstract Background Calcitonin gene‐related peptide (CGRP) is a key mediator in migraine pathophysiology, and the development of gepants, novel CGRP receptor antagonists, has expanded therapeutic options for both acute and preventive treatment. This scoping review aims to synthesize current evidence on the pharmacology, clinical applications, safety ...
Iannone LF, Silvestro M, Munafò A, Romozzi M, Geppetti P, Russo A.   +5 more
europepmc   +2 more sources

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial [PDF]

, 2023
Atogepant; Preventive treatment; MigraineAtogepant; Tractament preventiu; MigranyaAtogepant; Tratamiento preventivo; MigrañaBackground and Objectives The oral calcitonin gene–related peptide receptor antagonist atogepant is indicated for the preventive ...
Lipton, Richard B, Li, Ye, Blumenfeld, Andrew M, Pozo Rosich, Patricia, Stokes, Jonathan, Severt, Lawrence   +5 more
core   +3 more sources

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults

Clinical and Translational Science, 2021
Atogepant is a potent, selective, oral calcitonin gene–related peptide (CGRP) receptor antagonist in development for migraine prevention. The chemical structure of atogepant is distinct from previous CGRP receptor antagonists, which were associated with ...
K. Chris Min, Walter K. Kraft, Phung Bondiskey, Francheska Colón‐González, Wen Liu, Jialin Xu, Deborah Panebianco, Lori Mixson, Marissa F. Dockendorf, Catherine Z. Matthews, Ramesh Boinpally   +10 more
doaj   +1 more source

Safety and Tolerability Results of Atogepant for the Preventive Treatment of Episodic Migraine From a 40-Week, Open-Label Multicenter Extension of the Phase 3 ADVANCE Trial [PDF]

, 2023
Background: Atogepant is a United States Food and Drug Administration-approved oral calcitonin gene-related peptide receptor antagonist for the preventive treatment of episodic migraine.
Trugman, Joel M, Marmura, Michael J, Mechtler, Laszlo, Miceli, Rosa, McAllister, Peter, Klein, Brad C, Finnegan, Michelle, McVige, Jennifer, Severt, Lawrence, Diamond, Merle, Guo, Hua   +10 more
core   +1 more source

Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial [PDF]

, 2022
Migraine; Atogepant; AdultsMigraña; Atogepant; AdultosMigranya; Atogepant; AdultsImportance Some patients with migraine, particularly those in primary care, require effective, well-tolerated, migraine-specific oral preventive treatments.
Lipton, Richard B, Li, Ye, McAllister, Peter, Blumenfeld, Andrew M, Dodick, David W, Pozo Rosich, Patricia, Lu, Kaifeng, Dabruzzo, Brett, Finnegan, Michelle, Blumenfeld, Andrew M., Lipton, Richard B., Miceli, Rosa, Pozo-Rosich, Patricia, Trugman, Joel M., Dodick, David W., Severt, Lawrence, Ye Li, Michelle Finnegan, Brett Dabruzzo, Joel M. Trugman, Kaifeng Lu, Lawrence Severt, Peter McAllister, Richard B. Lipton, Patricia Pozo-Rosich, Rosa Miceli, Andrew M. Blumenfeld, David W. Dodick   +27 more
core   +3 more sources

Gepants for Acute and Preventive Migraine Treatment: A Narrative Review

Brain Sciences, 2022
Calcitonin gene-related peptide (CGRP) antagonists are a class of medications that act as antagonists of the CGRP receptor or ligand. They can be divided into monoclonal antibodies and non-peptide small molecules, also known as gepants.
Jamir Pitton Rissardo, Ana Letícia Fornari Caprara   +1 more
doaj   +1 more source

The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials

The Journal of Headache and Pain, 2022
Background Migraine is a common neurovascular disorder that has a severe impact on the individual daily life. Atogepant (AGN-241689) is an orally ingested, small-molecule drugs belonging to calcitonin gene-related peptide receptor antagonist, which has ...
Xinyu Tao, Zeya Yan, Jiahao Meng, Wei Wang, Qiling Dai, Qiufeng Zhou, Zhifeng Wang, Zhong Wang   +7 more
doaj   +1 more source